A multicenter, double-blind, randomized, active controlled, parallel group trial comparing the combinations of valsartan 80 mg plus hydrochlorothiazide 12.5 mg to valsartan 80 mg in patients with mild to moderate essential hypertension not adequately controlled with valsartan 80 mg.

Trial Profile

A multicenter, double-blind, randomized, active controlled, parallel group trial comparing the combinations of valsartan 80 mg plus hydrochlorothiazide 12.5 mg to valsartan 80 mg in patients with mild to moderate essential hypertension not adequately controlled with valsartan 80 mg.

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Apr 2017

At a glance

  • Drugs Valsartan/hydrochlorothiazide (Primary) ; Valsartan
  • Indications Essential hypertension
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 07 Nov 2011 Actual initiation date (Oct 2005) added as reported by ClinicalTrials.gov.
    • 07 Nov 2011 Actual end date (Jun 2006) added as reported by ClinicalTrials.gov.
    • 14 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top